Your browser doesn't support javascript.
loading
Do fetal extravillous trophoblasts circulate in maternal blood postpartum?
van de Looij, Anne; Singh, Ripudaman; Hatt, Lotte; Ravn, Katarina; Jeppesen, Line D; Nicolaisen, Bolette H; Kølvraa, Mathias; Vogel, Ida; Schelde, Palle; Uldbjerg, Niels.
Afiliación
  • van de Looij A; Department of Women's Disease and Birth, Aarhus University Hospital, Aarhus, Denmark.
  • Singh R; ARCEDI Biotech ApS, Vejle, Denmark.
  • Hatt L; ARCEDI Biotech ApS, Vejle, Denmark.
  • Ravn K; ARCEDI Biotech ApS, Vejle, Denmark.
  • Jeppesen LD; ARCEDI Biotech ApS, Vejle, Denmark.
  • Nicolaisen BH; ARCEDI Biotech ApS, Vejle, Denmark.
  • Kølvraa M; ARCEDI Biotech ApS, Vejle, Denmark.
  • Vogel I; Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark.
  • Schelde P; ARCEDI Biotech ApS, Vejle, Denmark.
  • Uldbjerg N; Department of Women's Disease and Birth, Aarhus University Hospital, Aarhus, Denmark.
Acta Obstet Gynecol Scand ; 99(6): 751-756, 2020 06.
Article en En | MEDLINE | ID: mdl-32323316
INTRODUCTION: Circulating fetal extravillous trophoblasts may offer a superior alternative to cell-free fetal DNA for noninvasive prenatal testing. Cells of fetal origin are a pure source of fetal genome; hence, unlike the cell-free noninvasive prenatal test, the fetal cell-based noninvasive prenatal test is not expected to be affected by maternal DNA. However, circulating fetal cells from previous pregnancies may lead to confounding results. MATERIAL AND METHODS: To study whether fetal trophoblast cells persist in maternal circulation postpartum, blood samples were collected from 11 women who had given birth to a boy, with blood sampling at 1-3 days (W0), 4-5 weeks (W4-5), around 8 weeks (W8) and around 12 weeks (W12) postpartum. The existence of fetal extravillous trophoblasts was verified either by X and Y chromosome fluorescence in situ hybridization analysis or by short tandem repeat analysis. To exclude technological bias in isolating fetal cells, blood samples were also collected from 10 pregnant women between a gestational age of 10 and 14 weeks, the optimal time frame for cell-based noninvasive prenatal test sampling. All the samples were processed according to protocols established by ARCEDI Biotech for fetal extravillous trophoblast enrichment and isolation. RESULTS: Fetal extravillous trophoblasts were found in all the 10 samples from pregnant women between a gestational age of 10 and 14 weeks. However, only 4 of 11 blood samples taken from women at 1-3 days postpartum rendered fetal extravillous trophoblasts, and only 2 of 11 samples rendered fetal extravillous trophoblasts at 4 weeks postpartum. CONCLUSIONS: In this preliminary dataset on few pregnancies, none of the samples rendered any fetal cells at or after 8 weeks postpartum, showing that cell-based noninvasive prenatal testing based on fetal extravillous trophoblasts is unlikely to be influenced by circulating cells from previous pregnancies.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trofoblastos / Periodo Posparto / Feto Límite: Female / Humans / Male / Pregnancy Idioma: En Revista: Acta Obstet Gynecol Scand Año: 2020 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trofoblastos / Periodo Posparto / Feto Límite: Female / Humans / Male / Pregnancy Idioma: En Revista: Acta Obstet Gynecol Scand Año: 2020 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Estados Unidos